Justera Announces 2023 AGM Results
Toronto, Ontario–(Newsfile Corp. – December 7, 2023) – Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) announces the voting results from the Annual General and Special Meeting of Shareholders (the “Meeting”) which was held on December 6, 2023.
At the Meeting, 38% of the issued and outstanding shares were represented in person or by proxy. Details of all resolutions that were voted upon are set out in the Management Information Circular (the “Circular”) dated November 2, 2023. The Circular is available on SEDAR+ (www.sedarplus.com).
All resolutions submitted for shareholder approval were approved, including:
- Receipt of the audited consolidated financial statements of the Company for the year ended December 31, 2022.
- Electing 3 directors of the Company: Ian Kim, Richard Yoon and Youngcho Lee.
- The appointment of SHIM & Associates LLP, Chartered Professional Accountants as the auditor of the Company.
- Approving the Company’s new Stock Option and RSU Plan.
About Justera Health
Established in 2020, Justera Health Ltd. is a Canadian Company focused on health and wellness. Through its services, innovative products, strategic partnerships, Justera empowers individuals to prioritize their well-being. With four subsidiaries, it offers personalized healthcare services and solutions, such as IV Vitamin Therapy, premium nutritional supplements through its Naturevan Nutrition brand, a full 360-degree wellness and spa experience through Juillet Wellness that provides registered massage therapy, acupuncture, and new retail stores in Vancouver. Justera’s mission is to enhance Canadians overall well-being with diverse solutions catering to individual needs.
For additional information on Justera Health and other corporate information, please visit the Company’s website at https://www.justerahealth.com.
For more information about the Company, please refer to the Company’s profile on SEDAR+ at www.sedarplus.com.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
For further information:
Investor Relations & Communications
Edward Park, Chief Executive Officer
Tel: (416) 901-5611 x 203
Email: epark@justerahealth.com
Forward-Looking Statements:
Certain statements contained in this news release may constitute forward-looking information, including statements relating to the future development of Justera’s business. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The actual results of Justera could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which Justera operates, prevailing economic conditions, changes to Justera’s strategic growth plans, and other factors, many of which are beyond the control of Justera. Management of Justera believes that the expectations reflected in the forward-looking information herein are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward‐looking information contained in this news release represents Justera’s expectations as of the date hereof and is subject to change after such date. Justera disclaims any intention or obligation to update or revise any forward‐looking information whether as a result of new information, future events, or otherwise, except as required by applicable securities legislation.
###
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/190207
